These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 32528527)

  • 1. Mitochondrial Toxicogenomics for Antiretroviral Management: HIV Post-exposure Prophylaxis in Uninfected Patients.
    Bañó M; Morén C; Barroso S; Juárez DL; Guitart-Mampel M; González-Casacuberta I; Canto-Santos J; Lozano E; León A; Pedrol E; Miró Ò; Tobías E; Mallolas J; Rojas JF; Cardellach F; Martínez E; Garrabou G
    Front Genet; 2020; 11():497. PubMed ID: 32528527
    [No Abstract]   [Full Text] [Related]  

  • 2. Adverse events and adherence to HIV post-exposure prophylaxis: a cohort study at the Korle-Bu Teaching Hospital in Accra, Ghana.
    Tetteh RA; Nartey ET; Lartey M; Mantel-Teeuwisse AK; Leufkens HG; Nortey PA; Dodoo AN
    BMC Public Health; 2015 Jun; 15():573. PubMed ID: 26092496
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mitochondrial toxicity in the era of HAART: evaluating venous lactate and peripheral blood mitochondrial DNA in HIV-infected patients taking antiretroviral therapy.
    Montaner JS; Côté HC; Harris M; Hogg RS; Yip B; Chan JW; Harrigan PR; O'Shaughnessy MV
    J Acquir Immune Defic Syndr; 2003 Sep; 34 Suppl 1():S85-90. PubMed ID: 14562863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tenofovir or zidovudine in three-drug combination therapy with one nucleoside reverse transcriptase inhibitor and one non-nucleoside reverse transcriptase inhibitor for initial treatment of HIV infection in antiretroviral-naïve individuals.
    Spaulding A; Rutherford GW; Siegfried N
    Cochrane Database Syst Rev; 2010 Oct; (10):CD008740. PubMed ID: 20927777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. WITHDRAWN. Effectiveness and safety of first-line tenofovir + emtricitabine + efavirenz for patients with HIV.
    Omeje I; Okwundu CI
    Cochrane Database Syst Rev; 2012 Feb; (2):CD007276. PubMed ID: 22336829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiretroviral therapy (ART) for treating HIV infection in ART-eligible pregnant women.
    Sturt AS; Dokubo EK; Sint TT
    Cochrane Database Syst Rev; 2010 Mar; (3):CD008440. PubMed ID: 20238370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Virological responses to lamivudine or emtricitabine when combined with tenofovir and a protease inhibitor in treatment-naïve HIV-1-infected patients in the Dutch AIDS Therapy Evaluation in the Netherlands (ATHENA) cohort.
    Rokx C; Gras L; van de Vijver D; Verbon A; Rijnders B;
    HIV Med; 2016 Sep; 17(8):571-80. PubMed ID: 26842457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo effects of highly active antiretroviral therapies containing the protease inhibitor nelfinavir on mitochondrially driven apoptosis.
    Miró O; Villarroya J; Garrabou G; López S; Rodríguez de la Concepción M; Pedrol E; Martínez E; Giralt M; Gatell JM; Cardellach F; Casademont J; Villarroya F
    Antivir Ther; 2005; 10(8):945-51. PubMed ID: 16430200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of adverse events associated with antiretroviral regimens for postexposure prophylaxis for occupational and nonoccupational exposures to prevent transmission of human immunodeficiency virus.
    Luque A; Hulse S; Wang D; Shahzad U; Tanzman E; Antenozzi S; Smith B
    Infect Control Hosp Epidemiol; 2007 Jun; 28(6):695-701. PubMed ID: 17520543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Side effects and tolerability of post-exposure prophylaxis with zidovudine, lamivudine, and lopinavir/ritonavir: a comparative study with HIV/AIDS patients.
    Cai J; Xiao J; Zhang Q
    Chin Med J (Engl); 2014; 127(14):2632-6. PubMed ID: 25043080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mitochondrial toxicity in hearts of CD-1 mice following perinatal exposure to AZT, 3TC, or AZT/3TC in combination.
    Chan SS; Santos JH; Meyer JN; Mandavilli BS; Cook DL; McCash CL; Kissling GE; Nyska A; Foley JF; van Houten B; Copeland WC; Walker VE; Witt KL; Bishop JB
    Environ Mol Mutagen; 2007; 48(3-4):190-200. PubMed ID: 16395692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tenofovir DF/emtricitabine/rilpivirine as HIV post-exposure prophylaxis: results from a multicentre prospective study.
    Chauveau M; Billaud E; Bonnet B; Merrien D; Hitoto H; Bouchez S; Michau C; Hall N; Perez L; Sécher S; Raffi F; Allavena C;
    J Antimicrob Chemother; 2019 Apr; 74(4):1021-1027. PubMed ID: 30689937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular biological assessment methods and understanding the course of the HIV infection.
    Katzenstein TL
    APMIS Suppl; 2003; (114):1-37. PubMed ID: 14626050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transplacentally exposed human and monkey newborn infants show similar evidence of nucleoside reverse transcriptase inhibitor-induced mitochondrial toxicity.
    Divi RL; Leonard SL; Kuo MM; Nagashima K; Thamire C; St Claire MC; Wade NA; Walker VE; Poirier MC
    Environ Mol Mutagen; 2007; 48(3-4):201-9. PubMed ID: 16538687
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of antiretroviral effect on mitochondrial DNA depletion among HIV-infected patients in Bali.
    Masyeni S; Sintya E; Megawati D; Sukmawati NMH; Budiyasa DG; Aryastuti SA; Khairunisa SQ; Arijana I; Nasronudin N
    HIV AIDS (Auckl); 2018; 10():145-150. PubMed ID: 30104903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective evaluation of blood concentration of mitochondrial DNA as a marker of toxicity in 157 consecutively recruited untreated or HAART-treated HIV-positive patients.
    Chiappini F; Teicher E; Saffroy R; Pham P; Falissard B; Barrier A; Chevalier S; Debuire B; Vittecoq D; Lemoine A
    Lab Invest; 2004 Jul; 84(7):908-14. PubMed ID: 15122308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in body composition and mitochondrial DNA in HIV-1-infected patients switching to fixed-dose abacavir/lamivudine or tenofovir/emtricitabine: a substudy of the BICOMBO trial.
    Curran A; Martinez E; Podzamczer D; Lonca M; Barragan P; Crespo M; Falco V; Vidal-Sicart S; Imaz A; Martinez M; Gatell JM; Ribera E
    Antivir Ther; 2012; 17(4):711-8. PubMed ID: 22374987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative Safety of Antiretroviral Treatment Regimens in Pregnancy.
    Zash R; Jacobson DL; Diseko M; Mayondi G; Mmalane M; Essex M; Petlo C; Lockman S; Makhema J; Shapiro RL
    JAMA Pediatr; 2017 Oct; 171(10):e172222. PubMed ID: 28783807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mitochondrial toxicity of tenofovir, emtricitabine and abacavir alone and in combination with additional nucleoside reverse transcriptase inhibitors.
    Venhoff N; Setzer B; Melkaoui K; Walker UA
    Antivir Ther; 2007; 12(7):1075-85. PubMed ID: 18018766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resistance profiles of emtricitabine and lamivudine in tenofovir-containing regimens.
    Marcelin AG; Charpentier C; Wirden M; Landman R; Valantin MA; Simon A; Katlama C; Yeni P; Descamps D; Aubron-Olivier C; Calvez V
    J Antimicrob Chemother; 2012 Jun; 67(6):1475-8. PubMed ID: 22371439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.